miR-204 Controls Glucagon-Like Peptide 1 Receptor Expression and Agonist Function

Area of Science:

• Endocrinology
• Molecular Biology
• Diabetes Research

Background:

• Glucagon-like peptide 1 receptor (GLP1R) agonists are crucial for diabetes treatment, but their efficacy relies on receptor expression, which decreases in diabetes.
• GLP1R on pancreatic beta cells mediates insulin secretion and glucose homeostasis via cAMP signaling.

Purpose of the Study:

• To investigate the role of microRNA-204 (miR-204) in regulating GLP1R expression in beta cells.
• To explore the impact of miR-204 and its upstream regulator, TXNIP, on GLP1R function and glucose metabolism in vivo.

Main Methods:

• Utilized beta-cell-derived cell lines (INS-1) and primary mouse and human islets to study miR-204's effect on GLP1R 3' UTR.
• Performed in vivo studies involving the deletion of miR-204 and TXNIP in mice.
• Assessed GLP1R expression, cAMP production, insulin secretion, and glucose tolerance in response to GLP1R agonists.

Main Results:

• Discovered that miR-204 directly targets and downregulates GLP1R expression in beta cells.
• In vivo deletion of miR-204 led to increased GLP1R expression, enhanced GLP1R agonist response, improved glucose tolerance, and protection against diabetes.
• Deletion of TXNIP mimicked the effects of miR-204 deletion, enhancing GLP1R expression and function.

Conclusions:

• Established miR-204 as a novel negative regulator of GLP1R in pancreatic beta cells.
• Uncovered a new link between TXNIP, miR-204, and incretin hormone action, offering potential therapeutic targets for diabetes.